APA (7th ed.) Citation

Lepper, A., Bitsch, R., Özbay Kurt, F. G., Arkhypov, I., Lasser, S., Utikal, J., & Umansky, V. (2023). Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs: Original research. OncoImmunology, 12(1), . https://doi.org/10.1080/2162402X.2023.2247303

Chicago Style (17th ed.) Citation

Lepper, Alisa, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, and Viktor Umansky. "Melanoma Patients with Immune-related Adverse Events After Immune Checkpoint Inhibitors Are Characterized by a Distinct Immunological Phenotype of Circulating T Cells and M-MDSCs: Original Research." OncoImmunology 12, no. 1 (2023). https://doi.org/10.1080/2162402X.2023.2247303.

MLA (9th ed.) Citation

Lepper, Alisa, et al. "Melanoma Patients with Immune-related Adverse Events After Immune Checkpoint Inhibitors Are Characterized by a Distinct Immunological Phenotype of Circulating T Cells and M-MDSCs: Original Research." OncoImmunology, vol. 12, no. 1, 2023, https://doi.org/10.1080/2162402X.2023.2247303.